BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30515764)

  • 1. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.
    Arachchillage DRJ; Alavian S; Griffin J; Gurung K; Szydlo R; Karawitage N; Laffan M
    Br J Haematol; 2019 Mar; 184(5):808-816. PubMed ID: 30515764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.
    Schulman S; Gross PL; Ritchie B; Nahirniak S; Lin Y; Lieberman L; Carrier M; Crowther MA; Ghosh I; Lazo-Langner A; Zondag M;
    Thromb Haemost; 2018 May; 118(5):842-851. PubMed ID: 29564837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.
    Majeed A; Ågren A; Holmström M; Bruzelius M; Chaireti R; Odeberg J; Hempel EL; Magnusson M; Frisk T; Schulman S
    Blood; 2017 Oct; 130(15):1706-1712. PubMed ID: 28835439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding.
    Sheikh-Taha M; Crawley RM
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):295-299. PubMed ID: 31709499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
    Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
    J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
    Sheikh-Taha M
    Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.
    Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
    Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
    Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
    Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
    Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
    Vinogradova Y; Coupland C; Hill T; Hippisley-Cox J
    BMJ; 2018 Jul; 362():k2505. PubMed ID: 29973392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban.
    Houghton DE; Casanegra AI; Peterson LG; Cochuyt J; Hodge DO; Vlazny D; McBane RD; Froehling D; Wysokinski WE
    Am J Hematol; 2020 Jul; 95(7):817-823. PubMed ID: 32267011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban.
    Barzilai M; Kirgner I; Steimatzky A; Salzer Gotler D; Belnick Y; Shacham-Abulafia A; Avivi I; Raanani P; Yahalom V; Nakav S; Varon D; Yussim E; Bachar GN; Spectre G
    Acta Haematol; 2020; 143(3):266-271. PubMed ID: 31610537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
    Panos NG; Cook AM; John S; Jones GM;
    Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.